Optimizing Clinical Trials for Patients with Chronic Disease

OMB 0925-0648

The Optimizing Clinical Trials for Patients with Chronic Disease workshop workshop workshop will identify areas of improvement in planning better clinical trials and will consider the key factors that are critical to a successful trial, including patient and stakeholder engagement, pre-trial analysis of the study population and landscape, with a focus on better planning and achieving optimal recruitment.

We are contacting you as a registrant for the purpose of gaining useful insight for framing content and areas for workshop discussion. The following questions should take approximately 20 minutes of your time. Thank you in advance for any and all feedback.

Public reporting burden for this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (9925-9648). Do not return the completed form to this address.

Responses to this survey are optional and you may exit it at any time.

Attendee Organization and Role Information
Please choose the category that best describes your organization:
University Industry Federal Agency Community Organization (Foundation, Service Organization, Advocacy Group) Other - Write In
Please choose one or more categories that best describes your relevant role in context of this workshop:
Trial Investigator Trial Coordinator Trial Methodologist (including operations) Trial Funder (including program officer) Community Engagement Expert Community Leader or Key Informant Funder Other - Write In
3. For projects in which you have personally participated (lead or collaborator), please indicate the number of:
Grants successfully funded to support a clinical trial? (to understand how many people design their own trials) (0-N) Industry sponsored trials as a participating site? (to understand how many people run protocols designed by industry) (0-N) Investigator-initiated, grant funded trials as a participating site? (to understand # people who participate in NIH funded trials as a participating site) (0-N)
Back Next

Attendee Perspective on Trial Barriers Related to Participant Engagement, Recruitment, and Retention

4. Based on your experience, please indicate the level of difficulty you've encountered around these common barriers to conducting successful NIH/NIDDK clinical trials (Please indicate 0-10 for each item for its difficulty. 0 easy, 10 most difficultive.)

0 1 2 3 4 5 6 7 8 9 10 O O O O O O O O

	1	2	3	4	5	6	7	8	9	10
0	0	0	0	0	6	0	0	8	0	0
	optimize NIH (specifically N		ation and planning discussi	ons? (Indicate all that app	Ny)					
Improved staff direct More robust FAQs	ory with targeted areas of	finterest								
Grants management	assistance									
Other - Write In										
ave you found the NIDDK	points of contacts listed in t	the clinical trial program and	nouncements helpful? (Y/N)						
○ Yes										
O No										
e you aware of NIH tools	and resources for assistance	be in planning clinical trials?	YN							
O Yes										
you have suggestions for	r improvement of current to	ols?								
Were there barriers to use	that you can share?									
23/16/0 10 036	,									
	4									
re there tools you think N	IH could supply that would	be helpful?								
	inference M									
					Ва	ck Next				
						ok Next				
What do you hope to I										
What do you hope to I	earn OR contribute by att	eending this workshop?			67%					
al Metrics	earn OR contribute by att	ending this workshop?	clinical trial in ClinicalTrials	s,gov within 365 days of 1	67%		y/clnica4-rials/reporting/u	nderstandinghil+policy.hin	n Summary results of NIH	-supported clinical Vales be sub-
What do you hope to I	earn OR contribute by att	ending this workshop?	clinical trial in ClinicalTrialetical	s.gov within 355 days of 1	67%		yicilnical-trials/reporting/uve	nderstanding/nih-policy.htm	n Summary results of NiH-H	-supported clinical trials be sub-
all Metrics so you aware of current first age of cu	earn OR contribute by att By policy requiring the representation of the ectual arimetry co. Clinical Trials, gory policy in	ending this workshop? Oring of 'final results' of a moleton date.			67%	https://grants.nih.gov/polic				
al Metrics al working of country to the service of country to the serv	earn OR contribute by att	ending this workshop? Oring of 'final results' of a moleton date.			67%	https://grants.nih.gov/polic				-supported clinical trials be sub-
al Metrics sy you awas of current NN and ago within 365 car	earn OR contribute by att By policy requiring the representation of the ectual arimetry co. Clinical Trials, gory policy in	ending this workshop? Oring of 'final results' of a moleton date.			67%	https://grants.nih.gov/polic				
all Metrics systematics of current Nill and the State State Yes No No No No	ann OR contribute by att BH policy requiring the reper ye of the actual gitmans.co. Clinical Trials, gov policy in clicicity to answer the print	orting of "final results" of a moletion date.	minated early as well as st	tudies that completed thei	primary results reporting"?	https://grants.nih.gov/polic results reporting * Do you	think it is important to the	research community to inc	clude a separate metric for	
all Metrics all Metrics by you awas of current to the state of the sta	let policy requiring the representation of the actual orimator so of the actual orimator. So of the actual orimator so of the actual orimator. So of the actual orimator so of the actual orimator. So of the actual orimator so of the actual orimator so of the actual orimator. So of the actual orimator so of the actual orimator so of the actual orimator.	orting of "final results" of a moletion state.	minated early as well as st	tudies that completed their	primary results reporting? ir original goals as "primary question (le, "failed triels",	https://grants.nih.gov/polic results reporting * Do you	think it is important to the	research community to inc	clude a separate metric for	r assessing how many clinical t
al Metrics sy you awar of comment in this growth and the growth an	ann OR contribute by att BH policy requiring the reper ye of the actual gitmans.co. Clinical Trials, gov policy in clicicity to answer the print	ending this workshop? orting of "final results" of a mistellion date. clude studies that were ter any research question out dinical triels that did N, participant time and eff	minated early as well as st OT provide a definitive ans	tudies that completed their sources of the primary study sted/minimized as aggre	primary results reporting? ir original goals as "primary question (le, "failed triels",	https://grants.nih.gov/polic results reporting * Do you	think it is important to the	research community to inc	clude a separate metric for	r assessing how many clinical t
all Metrics by you award of unrent his fact of unre	aern OR contribute by att BH policy requiring the reper ye of the actual grimany.co. ClinicalTrials gov policy in- icidently to answer the primit describes your attitude ab wasted taxpayer money wasted taxpayer money	criting of "final results" of a moletion date. Clude studies that were ter any research question out clinical trials that did N., participant time and eff are of clinical trials, and	minated early as well as st OT provide a definitive ans	tudies that completed their sources of the primary study sted/minimized as aggre	primary results reporting? ir original goals as "primary question (le, "failed triels",	https://grants.nih.gov/polic results reporting * Do you	think it is important to the	research community to inc	clude a separate metric for	r assessing how many clinical t
al Metrics al Metrics you enser of current Nill and above, current Nill and affectively have their goods (curl Nill and So de No. No. 19 No. 1	aern OR contribute by att BH policy requiring the respect See of the actual attinuary co- clicical Trials, gov policy in clicical Trials, gov policy in clicical to answer the primi describes your attitude ab wasted taxpayer money avoidable part of the nata gnificant disincentive to	orting of "final results" of a moletion date. clude studies that were ter any research question out clinical triels that did N , participant time and eff ure of clinical trials, and enrolling patients.	minimated early as well as at OT provide a definitive and orr, and should be avoid efforts to address them s	tudies that completed their beautiful to the primary study seed immirror study seed immirror study be misguided.	primary results reporting?? ir original goals as "primary question (le, "failed tricis",	https://grants.nih.gov/polic results reporting * Do you as opposed either yes the	think it is important to the	research community to inc	clude a separate metric for	r assessing how many clinical t
al Metrics al Metrics you enser of current Nill and above, current Nill and affectively have their goods (curl Nill and So de No. No. 19 No. 1	aern OR contribute by att BH policy requiring the respect See of the actual attinuary co- clicical Trials, gov policy in clicical Trials, gov policy in clicical to answer the primi describes your attitude ab wasted taxpayer money avoidable part of the nata gnificant disincentive to	orting of "final results" of a moletion date. clude studies that were ter any research question out clinical triels that did N , participant time and eff ure of clinical trials, and enrolling patients.	minimated early as well as at OT provide a definitive and orr, and should be avoid efforts to address them s	tudies that completed their state of the primary study ted iminimized as aggree would be misguided.	primary results reporting? ir original goals as "primary question (le, "failed triels",	https://grants.nih.gov/polic results reporting * Do you as opposed either yes the	think it is important to the	research community to inc	clude a separate metric for	r assessing how many clinical t

